|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: POMGNT1 |
Gene summary for POMGNT1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | POMGNT1 | Gene ID | 55624 |
| Gene name | protein O-linked mannose N-acetylglucosaminyltransferase 1 (beta 1,2-) | |
| Gene Alias | GNTI.2 | |
| Cytomap | 1p34.1 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | B7Z7Q4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55624 | POMGNT1 | P61T-E | Human | Esophagus | ESCC | 7.26e-19 | 3.21e-01 | 0.099 |
| 55624 | POMGNT1 | P62T-E | Human | Esophagus | ESCC | 6.16e-22 | 3.48e-01 | 0.1302 |
| 55624 | POMGNT1 | P65T-E | Human | Esophagus | ESCC | 1.52e-11 | 2.07e-01 | 0.0978 |
| 55624 | POMGNT1 | P74T-E | Human | Esophagus | ESCC | 2.09e-12 | 2.96e-01 | 0.1479 |
| 55624 | POMGNT1 | P75T-E | Human | Esophagus | ESCC | 6.46e-09 | 2.56e-01 | 0.1125 |
| 55624 | POMGNT1 | P76T-E | Human | Esophagus | ESCC | 3.27e-21 | 3.37e-01 | 0.1207 |
| 55624 | POMGNT1 | P79T-E | Human | Esophagus | ESCC | 9.34e-10 | 2.26e-01 | 0.1154 |
| 55624 | POMGNT1 | P80T-E | Human | Esophagus | ESCC | 2.10e-19 | 5.38e-01 | 0.155 |
| 55624 | POMGNT1 | P82T-E | Human | Esophagus | ESCC | 1.80e-04 | 3.24e-01 | 0.1072 |
| 55624 | POMGNT1 | P83T-E | Human | Esophagus | ESCC | 4.72e-22 | 4.42e-01 | 0.1738 |
| 55624 | POMGNT1 | P89T-E | Human | Esophagus | ESCC | 1.56e-02 | 2.18e-01 | 0.1752 |
| 55624 | POMGNT1 | P91T-E | Human | Esophagus | ESCC | 3.21e-04 | 9.96e-01 | 0.1828 |
| 55624 | POMGNT1 | P107T-E | Human | Esophagus | ESCC | 5.99e-17 | 2.74e-01 | 0.171 |
| 55624 | POMGNT1 | P126T-E | Human | Esophagus | ESCC | 8.47e-03 | 6.50e-01 | 0.1125 |
| 55624 | POMGNT1 | P127T-E | Human | Esophagus | ESCC | 9.84e-17 | 1.61e-01 | 0.0826 |
| 55624 | POMGNT1 | P128T-E | Human | Esophagus | ESCC | 1.09e-12 | 4.35e-01 | 0.1241 |
| 55624 | POMGNT1 | P130T-E | Human | Esophagus | ESCC | 1.89e-31 | 7.23e-01 | 0.1676 |
| 55624 | POMGNT1 | HCC1_Meng | Human | Liver | HCC | 1.45e-52 | 8.25e-02 | 0.0246 |
| 55624 | POMGNT1 | HCC2_Meng | Human | Liver | HCC | 3.79e-15 | 7.68e-02 | 0.0107 |
| 55624 | POMGNT1 | HCC1 | Human | Liver | HCC | 1.67e-08 | 4.71e+00 | 0.5336 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
| GO:00700854 | Esophagus | ESCC | glycosylation | 144/8552 | 240/18723 | 5.12e-06 | 5.38e-05 | 144 |
| GO:00064865 | Esophagus | ESCC | protein glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00434135 | Esophagus | ESCC | macromolecule glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
| GO:00064931 | Esophagus | ESCC | protein O-linked glycosylation | 51/8552 | 86/18723 | 7.54e-03 | 2.70e-02 | 51 |
| GO:00064862 | Liver | HCC | protein glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
| GO:00434132 | Liver | HCC | macromolecule glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
| GO:00700852 | Liver | HCC | glycosylation | 128/7958 | 240/18723 | 4.35e-04 | 2.92e-03 | 128 |
| GO:0009100 | Liver | HCC | glycoprotein metabolic process | 193/7958 | 387/18723 | 1.89e-03 | 9.62e-03 | 193 |
| GO:00091001 | Oral cavity | OSCC | glycoprotein metabolic process | 185/7305 | 387/18723 | 2.37e-04 | 1.54e-03 | 185 |
| GO:00091011 | Oral cavity | OSCC | glycoprotein biosynthetic process | 151/7305 | 317/18723 | 1.01e-03 | 5.26e-03 | 151 |
| GO:00064864 | Oral cavity | OSCC | protein glycosylation | 111/7305 | 226/18723 | 1.22e-03 | 6.10e-03 | 111 |
| GO:00434134 | Oral cavity | OSCC | macromolecule glycosylation | 111/7305 | 226/18723 | 1.22e-03 | 6.10e-03 | 111 |
| GO:00700853 | Oral cavity | OSCC | glycosylation | 117/7305 | 240/18723 | 1.29e-03 | 6.42e-03 | 117 |
| GO:007008511 | Oral cavity | LP | glycosylation | 77/4623 | 240/18723 | 5.60e-03 | 3.38e-02 | 77 |
| GO:000648611 | Oral cavity | LP | protein glycosylation | 73/4623 | 226/18723 | 5.72e-03 | 3.44e-02 | 73 |
| GO:004341311 | Oral cavity | LP | macromolecule glycosylation | 73/4623 | 226/18723 | 5.72e-03 | 3.44e-02 | 73 |
| GO:00064866 | Thyroid | PTC | protein glycosylation | 94/5968 | 226/18723 | 1.25e-03 | 7.13e-03 | 94 |
| GO:00434136 | Thyroid | PTC | macromolecule glycosylation | 94/5968 | 226/18723 | 1.25e-03 | 7.13e-03 | 94 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| POMGNT1 | SNV | Missense_Mutation | novel | c.1313N>T | p.Ala438Val | p.A438V | Q8WZA1 | protein_coding | possibly_damaging(0.524) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response | |
| POMGNT1 | SNV | Missense_Mutation | c.2120N>T | p.Ala707Val | p.A707V | Q8WZA1 | protein_coding | benign(0.076) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| POMGNT1 | SNV | Missense_Mutation | novel | c.1540G>C | p.Glu514Gln | p.E514Q | Q8WZA1 | protein_coding | possibly_damaging(0.707) | TCGA-C8-A3M7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| POMGNT1 | SNV | Missense_Mutation | c.455A>G | p.Tyr152Cys | p.Y152C | Q8WZA1 | protein_coding | probably_damaging(0.997) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| POMGNT1 | SNV | Missense_Mutation | rs778179887 | c.1157C>T | p.Ala386Val | p.A386V | Q8WZA1 | protein_coding | probably_damaging(0.997) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| POMGNT1 | SNV | Missense_Mutation | c.1247N>G | p.Asp416Gly | p.D416G | Q8WZA1 | protein_coding | probably_damaging(0.997) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | ||
| POMGNT1 | SNV | Missense_Mutation | c.1184N>G | p.Asp395Gly | p.D395G | Q8WZA1 | protein_coding | probably_damaging(1) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| POMGNT1 | SNV | Missense_Mutation | c.2009N>G | p.Phe670Cys | p.F670C | Q8WZA1 | protein_coding | probably_damaging(0.971) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | ||
| POMGNT1 | SNV | Missense_Mutation | c.589G>T | p.Gly197Cys | p.G197C | Q8WZA1 | protein_coding | probably_damaging(1) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
| POMGNT1 | SNV | Missense_Mutation | rs756234628 | c.800N>A | p.Arg267His | p.R267H | Q8WZA1 | protein_coding | benign(0.36) | TCGA-D5-6930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |